



# BERGENBIO PRESENTS CLINICAL DATA ON BEMCENTINIB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NSCLC AT ASCO ANNUAL MEETING 2022

**Bergen, Norway, 6 June 2022** – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, is pleased to announce presentation of a poster at the ASCO Annual Meeting to be held from 3<sup>rd</sup> - 8<sup>th</sup> June 2022.

The poster presentation provides clinical data from a Phase 1 dose escalation and expansion study of bemcentinib (BGB324) in combination with docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). The data presented indicate that bemcentinib in combination with docetaxel shows evidence of anti-tumor activity, with 35% of patients achieving a partial response and 47% attaining stable disease, and a manageable safety profile in previously treated, advanced NSCLC.

**Cristina Oliva, Chief Medical Officer at BerGenBio**, commented: "While the data are limited, they suggest a mechanism by which treatment with bemcentinib could delay resistance to and potentiate the effects of chemotherapy treatment in NSCLC patients."

The full abstract is available on the ASCO website here:  
<https://meetings.asco.org/abstracts-presentations/212839>

Full details of the presentation are below:

**Title:** *Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced NSCLC.*

**Author:** Bhalla et al.

**Session/Abstract ID:** Lung Cancer – Non Small Cell Metastatic / 9081

**Location/Time:** June 6, 2022, Hall D1, 1:25pm Central Time

## **Contacts:**

Martin Olin CEO, BerGenBio ASA  
[ir@bergenbio.com](mailto:ir@bergenbio.com)

Rune Skeie, CFO, BerGenBio ASA  
[rune.skeie@bergenbio.com](mailto:rune.skeie@bergenbio.com)

### **International Media Relations**

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone  
Consilium Strategic Communications  
[bergenbio@consilium-comms.com](mailto:bergenbio@consilium-comms.com)  
+44 20 3709 5700

### **About BerGenBio ASA**

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit [www.bergenbio.com](http://www.bergenbio.com)

### **Forward looking statements**

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

**This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.**